Mutational signatures may ID pts with Br Ca most likely to benefit from platinum-based chemo

(American Association for Cancer Research) The presence in advanced breast cancer of mutational signatures characteristic of homologous recombination deficiency (HRD) was associated with improved clinical outcomes to treatment with platinum-based chemotherapy.